Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Humanized CD19 CAR-T Cells With TLR2 for Adult B-ALL/LBL Intolerant to Intensive Chemotherapy
NCT07335094Phase 1Not yet recruiting
- Sponsor
- Southern Medical University Zhujiang Hospital
- Start
- Jun 2026
- Primary completion
- Jun 2028
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
01
Overview
Phase 1, open-label, single-arm trial of humanized CD19 CAR-T cells with TLR2 in B cell acute lymphoblastic leukemia (B-ALL) and B-cell lymphoblastic lymphoma (B-LBL), sponsored by Southern Medical University Zhujiang Hospital. Primary endpoint: Objective Response Rate at 3 years. Planned start Jun 2026; status: not yet recruiting.
02
Drugs
humanized CD19 CAR-T cells with TLR2
03
Conditions
B cell acute lymphoblastic leukemia (B-ALL)B-cell lymphoblastic lymphoma (B-LBL)
Beyond the preview
Go deeper on NCT07335094.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07335094.